An isolated peptide of less than 15 amino acids capable of inducing cytotoxic T lymphocytes (CTLs), wherein the peptide comprises an amino acid sequence (a) or (b) below: (a) an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25, 27, 29, 30, 32, 36, 38, 41, 48, 49, 51, 52, 53, 55, 56 and 58; or (b) an amino acid sequence in which 1 or 2 amino acid(s) are substituted and/or added in the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25, 27, 29, 30, 32, 36, 38, 41, 48, 49, 51, 52, 53, 55, 56 and 58; wherein the substitutions are selected from the group consisting of (i) and (ii) as follows: (i) a peptide that has one or both of the following characteristics: (a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25 or 27 is substituted with phenylalanine, tyrosine, methionine or tryptophan; and (b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25 or 27 is substituted with phenylalanine, leucine, isoleucine, tryptophan or methionine; or (ii) a peptide that has one or both of the following characteristics: (a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 48, 29, 30, 32, 36, 38, 41, 49, 51, 52, 53, 55, 56 or 58 is substituted with leucine or methionine; and (b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 48, 29, 30, 32, 36, 38, 41, 49, 51, 52, 53, 55, 56 or 58 is substituted with valine or leucine; and wherein the amino acids, if added, are added to the N and/or C-terminus of the peptide. (a) an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25, 27, 29, 30, 32, 36, 38, 41, 48, 49, 51, 52, 53, 55, 56 and 58; or (b) an amino acid sequence in which 1 or 2 amino acid(s) are substituted and/or added in the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25, 27, 29, 30, 32, 36, 38, 41, 48, 49, 51, 52, 53, 55, 56 and 58; (i) a peptide that has one or both of the following characteristics: (a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25 or 27 is substituted with phenylalanine, tyrosine, methionine or tryptophan; and (b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25 or 27 is substituted with phenylalanine, leucine, isoleucine, tryptophan or methionine; or (a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25 or 27 is substituted with phenylalanine, tyrosine, methionine or tryptophan; and (b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 1, 2, 4, 6, 11, 12, 13, 15, 17, 19, 20, 21, 22, 23, 24, 25 or 27 is substituted with phenylalanine, leucine, isoleucine, tryptophan or methionine; or (ii) a peptide that has one or both of the following characteristics: (a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 48, 29, 30, 32, 36, 38, 41, 49, 51, 52, 53, 55, 56 or 58 is substituted with leucine or methionine; and (b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 48, 29, 30, 32, 36, 38, 41, 49, 51, 52, 53, 55, 56 or 58 is substituted with valine or leucine; and (a) the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 48, 29, 30, 32, 36, 38, 41, 49, 51, 52, 53, 55, 56 or 58 is substituted with leucine or methionine; and (b) the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 48, 29, 30, 32, 36, 38, 41, 49, 51, 52, 53, 55, 56 or 58 is substituted with valine or leucine; and